Roland Meier, M.D., Ph.D

Roland has over 20 years of experience in clinical practice, research, and industry in all phases of drug development. He has served in immuno-oncology leadership roles at Bristol Myers Squibb, Eli Lilly, and most recently at Kyowa Kirin. Earlier in his career, Roland worked in Medical Affairs, Drug Safety, and Clinical Development. Roland has worked on multiple therapeutics from Phase 1 to Phase 4. He has contributed to commercially available drugs including Jevtana, Kadcyla, Herceptin, Avastin, Venclexta, Empliciti, and Poteligeo. His immuno-oncology contributions includes checkpoint inhibitors Opdivo and Yervoy and various immune-stimulatory T-cell agonists including urelumab (4-1BB and GITR); and other immuno-modulatory agents including IDO inhibitors and RNA vaccines.

During his postdoctoral fellowship at the Lawrence Berkeley National Laboratory, Roland investigated the role of the tumor microenvironment on tumor initiation and progression and characterized a protein that could mediate resistance to targeted therapy in breast cancer.

After Roland graduated with an MD from the University of Zurich, Switzerland, he worked as a resident at the Children’s Hospital of Zurich and subsequently at the University Hospital in Lausanne, Switzerland where he pursued his passion for research and was awarded an M.D., Ph.D.